Michael Crowley Sells 700 Shares of Bio-Rad Laboratories, Inc. (BIO) Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Michael Crowley sold 700 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now directly owns 2,060 shares in the company, valued at $444,774.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 215.89 on Friday. Bio-Rad Laboratories, Inc. has a one year low of $147.68 and a one year high of $242.79. The company has a market cap of $6.40 billion, a PE ratio of 426.66 and a beta of 0.91. The stock’s 50 day moving average is $229.16 and its 200-day moving average is $212.40.

WARNING: This story was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://transcriptdaily.com/2017/08/13/michael-crowley-sells-700-shares-of-bio-rad-laboratories-inc-bio-stock.html.

BIO has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 price objective on the stock in a research report on Monday, May 1st. Jefferies Group LLC reissued a “buy” rating and set a $250.00 price objective on shares of Bio-Rad Laboratories in a research report on Thursday, April 27th. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price objective on the stock. TheStreet downgraded shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Finally, Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and reduced their price objective for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $228.80.

Several institutional investors have recently made changes to their positions in BIO. Canada Pension Plan Investment Board purchased a new position in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Pacad Investment Ltd. purchased a new position in shares of Bio-Rad Laboratories during the second quarter valued at approximately $113,000. Advisory Services Network LLC purchased a new position in shares of Bio-Rad Laboratories during the first quarter valued at approximately $115,000. Flinton Capital Management LLC raised its position in shares of Bio-Rad Laboratories by 17.6% in the first quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock valued at $128,000 after buying an additional 96 shares in the last quarter. Finally, Turner Investments LLC purchased a new position in shares of Bio-Rad Laboratories during the second quarter valued at approximately $136,000. Hedge funds and other institutional investors own 63.73% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply